Noma and Novonesis partner to scale deliciousness Noma and Novonesis partner to scale deliciousnessNoma, hailed as one of the world’s best restaurants, is joining forces with Novonesis, the global leader in biosolutions, to take deliciousness to the next level. Together, they’re fusing culinary craft with biology to create flavors and products that are healthier, tastier, and better for the planet. COPENHAGEN, 23 October 2025: Innovation pushes boundaries and, at times, returns to the beginning. For thousands of years, we have used biology to craft our rich tapestry of food and beverage tr...
Novonesis Hosts National Flagship Manufacturing Day Event at North America Headquarters Franklinton, NC, Oct. 06, 2025 (GLOBE NEWSWIRE) -- , a global leader in biosolutions, welcomed hundreds of local students, educators, and community leaders to its facilities in Salem, Virginia; West Allis and Madison, Wisconsin; and its North American headquarters in Franklinton, North Carolina, for the national flagship (MFG Day), a grassroots movement of the (MI). The MI is the workforce development and education affiliate of (NAM). The MI’s mission is to build and strengthen the manufacturing workfo...
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. COPENHAGEN, Denmark – September 8, 2025. Novonesis and Novo Nordisk has entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The gut microbiome is the collection of microorganisms, such as bacteria, fungi, and viruses, that naturally live in the human gut. The science...
Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8% COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place, ...
Interim report H1 2025 9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a robust foundation in place, we are well positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what mak...
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The...
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.